Canada's Bausch to pay $300M in an­titrust set­tle­ment; Cardiff re­leas­es da­ta on mCRC tri­al

Cana­di­an phar­ma com­pa­ny Bausch Health has agreed to set­tle an an­titrust class-ac­tion suit from a 2015 price in­crease.

Ac­cord­ing to Reuters, the class-ac­tion law­suit ac­cused Bausch of main­tain­ing an il­le­gal mo­nop­oly on di­a­betes drug Glumet­za, en­abling a price hike of near­ly 800% in 2015 from $5.72 to $51 per tablet.

Lawyers for com­pa­nies that bought Glumet­za and filed the suit against Bausch re­vealed the deal in a court fil­ing on Wednes­day, ask­ing US Dis­trict Judge William Al­sup in San Fran­cis­co to ap­prove it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER